Edwards Lifesciences Appoints Theodora Mistras as New CFO

summarizeSummary

Edwards Lifesciences has appointed Theodora Mistras, formerly CFO of Viatris, as its new Chief Financial Officer, effective May 29, 2026, completing a previously announced leadership transition.

check_boxKey Events

• New CFO Appointed

  Theodora Mistras has been appointed Corporate Vice President, Chief Financial Officer, effective May 29, 2026. She succeeds Scott B. Ullem, whose transition was previously announced in October.

• Extensive Financial Background

  Ms. Mistras previously served as Chief Financial Officer of Viatris, Inc. since March 2024, and prior to that, held senior leadership roles in healthcare investment banking at Citigroup Global Markets and Goldman Sachs for over 15 years.

• Compensation Details

  Her compensation package includes an annual base salary of $925,000, a target annual bonus of 100% of base salary, a $2,013,000 sign-on bonus, and initial equity awards totaling $12,500,000 ($8,000,000 in new hire RSUs and a $4,500,000 annual equity grant for fiscal year 2026).

auto_awesomeAnalysis

This 8-K announces the appointment of Theodora Mistras as the new Chief Financial Officer, effective May 29, 2026. This completes a planned succession, as the departure of the previous CFO, Scott B. Ullem, was announced in October. Ms. Mistras brings extensive experience from her previous role as CFO of Viatris and a long career in healthcare investment banking, which is a positive signal for the company's financial leadership. The compensation package, while substantial in absolute terms, is typical for a CFO at a large-cap company and reflects the importance of the role in maintaining financial stewardship and strategic direction.